Aurora Cannabis (ACB) Downgraded to D+ at TheStreet

TheStreet downgraded shares of Aurora Cannabis (NYSE:ACB) from a c rating to a d+ rating in a report published on Monday, February 25th. Several …

Aurora Cannabis Inc logoTheStreet downgraded shares of Aurora Cannabis (NYSE:ACB) from a c rating to a d+ rating in a report published on Monday, February 25th.

Several other analysts have also weighed in on ACB. GMP Securities reissued a hold rating and issued a $9.50 price objective on shares of Aurora Cannabis in a report on Tuesday, February 12th. Seaport Global Securities assumed coverage on Aurora Cannabis in a report on Thursday, February 21st. They set a neutral rating for the company. Finally, Jefferies Financial Group assumed coverage on Aurora Cannabis in a report on Monday, February 25th. They set a buy rating for the company. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $9.50.

Shares of NYSE:ACB traded down $0.08 during trading on Monday, hitting $8.99. The company’s stock had a trading volume of 56,250,495 shares, compared to its average volume of 29,169,904. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.50 and a current ratio of 3.31. Aurora Cannabis has a fifty-two week low of $4.05 and a fifty-two week high of $12.52. The stock has a market cap of $8.06 billion, a price-to-earnings ratio of 74.92 and a beta of 2.90.

Aurora Cannabis (NYSE:ACB) last released its quarterly earnings results on Monday, February 11th. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. The business had revenue of $41.00 million for the quarter. Aurora Cannabis had a positive return on equity of 3.95% and a negative net margin of 57.54%. On average, equities research analysts predict that Aurora Cannabis will post -0.17 EPS for the current year.

Several large investors have recently bought and sold shares of the company. Financial Advocates Investment Management bought a new position in Aurora Cannabis in the 4th quarter worth approximately $74,000. Flagship Harbor Advisors LLC bought a new position in Aurora Cannabis in the 4th quarter worth approximately $26,000. Advisory Services Network LLC bought a new position in Aurora Cannabis in the 4th quarter worth approximately $29,000. Trustcore Financial Services LLC bought a new position in Aurora Cannabis in the 4th quarter worth approximately $33,000. Finally, Farmers & Merchants Trust Co of Chambersburg PA bought a new position in Aurora Cannabis in the 4th quarter worth approximately $36,000. 8.16% of the stock is owned by institutional investors.

About Aurora Cannabis

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

Read More: What are the reasons investors use put options?

Receive News & Ratings for Aurora Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurora Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Jefferies Financial Group Reiterates Buy Rating for Aurora Cannabis (ACB)

Jefferies Financial Group restated their buy rating on shares of Aurora Cannabis (TSE:ACB) in a research report released on Monday, February 25th.

Aurora Cannabis Inc logoJefferies Financial Group restated their buy rating on shares of Aurora Cannabis (TSE:ACB) in a research report released on Monday, February 25th. They currently have a C$12.00 target price on the stock.

ACB has been the subject of a number of other research reports. Eight Capital cut their price target on Aurora Cannabis from C$17.00 to C$15.00 in a research note on Wednesday, January 9th. Seaport Global Securities reissued a neutral rating on shares of Aurora Cannabis in a report on Thursday, February 21st. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of C$13.50.

Shares of ACB stock traded down C$0.10 during midday trading on Monday, reaching C$11.92. 20,566,041 shares of the stock were exchanged, compared to its average volume of 18,717,105. The company has a debt-to-equity ratio of 8.08, a quick ratio of 1.89 and a current ratio of 3.31. Aurora Cannabis has a 1 year low of C$5.29 and a 1 year high of C$16.24. The company has a market capitalization of $10.77 billion and a price-to-earnings ratio of -120.40.

Aurora Cannabis (TSE:ACB) last released its quarterly earnings data on Monday, February 11th. The company reported C($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of C($0.06) by C$0.01. The business had revenue of C$54.18 million during the quarter, compared to the consensus estimate of C$52.13 million. Sell-side analysts forecast that Aurora Cannabis will post 0.0300000005785921 earnings per share for the current year.

A hedge fund recently bought a new stake in Aurora Cannabis stock. Gulf International Bank UK Ltd acquired a new stake in shares of Aurora Cannabis Inc (TSE:ACB) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 11,669 shares of the company’s stock, valued at approximately $112,000.

Aurora Cannabis Company Profile

Aurora Cannabis Inc is a Canada-based company engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis, and hemp production, derivatives, home cultivation, wholesale and retail distribution.

Recommended Story: Cost of Equity For A Business, Investors

Analyst Recommendations for Aurora Cannabis (TSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurora Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Investors Buy Aurora Cannabis (ACB) on Weakness

Investors bought shares of Aurora Cannabis Inc (NYSE:ACB) on weakness during trading on Thursday. $131.48 million flowed into the stock on the …

Aurora Cannabis logoInvestors bought shares of Aurora Cannabis Inc (NYSE:ACB) on weakness during trading on Thursday. $131.48 million flowed into the stock on the tick-up and $92.16 million flowed out of the stock on the tick-down, for a money net flow of $39.32 million into the stock. Of all stocks tracked, Aurora Cannabis had the 22nd highest net in-flow for the day. Aurora Cannabis traded down ($0.08) for the day and closed at $8.99

ACB has been the subject of a number of research analyst reports. Seaport Global Securities initiated coverage on Aurora Cannabis in a report on Thursday, February 21st. They issued a “neutral” rating for the company. GMP Securities reaffirmed a “hold” rating and issued a $9.50 price target on shares of Aurora Cannabis in a report on Tuesday, February 12th. Cowen initiated coverage on Aurora Cannabis in a report on Tuesday, March 5th. They issued an “outperform” rating for the company. Jefferies Financial Group initiated coverage on Aurora Cannabis in a report on Monday, February 25th. They issued a “buy” rating for the company. Finally, TheStreet downgraded Aurora Cannabis from a “c” rating to a “d+” rating in a report on Monday, February 25th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $9.50.

The company has a quick ratio of 2.50, a current ratio of 3.31 and a debt-to-equity ratio of 0.08. The firm has a market cap of $8.06 billion, a PE ratio of 74.92 and a beta of 2.90.

Aurora Cannabis (NYSE:ACB) last announced its quarterly earnings results on Monday, February 11th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.02. The firm had revenue of $41.00 million during the quarter. Aurora Cannabis had a positive return on equity of 3.95% and a negative net margin of 57.54%. As a group, research analysts predict that Aurora Cannabis Inc will post -0.17 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. ETF Managers Group LLC acquired a new stake in shares of Aurora Cannabis in the fourth quarter valued at approximately $40,454,000. Norges Bank acquired a new stake in shares of Aurora Cannabis in the fourth quarter valued at approximately $30,915,000. TD Asset Management Inc. acquired a new stake in shares of Aurora Cannabis in the fourth quarter valued at approximately $16,657,000. JW Asset Management LLC acquired a new stake in shares of Aurora Cannabis in the fourth quarter valued at approximately $10,734,000. Finally, D. E. Shaw & Co. Inc. acquired a new stake in shares of Aurora Cannabis in the fourth quarter valued at approximately $10,504,000. 8.16% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Investors Buy Aurora Cannabis (ACB) on Weakness” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.baseballdailydigest.com/news/2019/03/14/investors-buy-aurora-cannabis-acb-on-weakness.html.

Aurora Cannabis Company Profile (NYSE:ACB)

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

Featured Story: Certificate of Deposit (CD)

Receive News & Ratings for Aurora Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurora Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Why AI will make healthcare personal

Now, as emerging technologies such as artificial intelligence open up new possibilities for the healthcare industry in the Fourth Industrial Revolution, …

AI is also the driving force behind precision medicine, which uses information about a person’s environment, lifestyle and biology, including in their DNA, to diagnose and treat diseases. By analyzing a patient’s information, doctors are able to prescribe the treatments that are most likely to be effective, as well as minimize drug reactions and unwanted side effects. As the World Economic Forum’s head of precision medicine, Genya Dana, says, it’s “the right treatment for the right person at the right time.”

Related Posts:

  • No Related Posts

iCAD Reports Strong Momentum of ProFound AI™, its Artificial Intelligence-Based Solution for …

The powerful solution built on artificial intelligence (AI) delivers critical benefits to radiologists, their facilities and patients in identifying cancer earlier.

NASHUA, N.H.–(BUSINESS WIRE)–Mar 14, 2019–iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported strong adoption of its latest deep-learning, cancer detection software solution for digital breast tomosynthesis (DBT), ProFound AI™. The powerful solution built on artificial intelligence (AI) delivers critical benefits to radiologists, their facilities and patients in identifying cancer earlier.

“ProFound AI for DBT is like having another radiologist right there in the reading room with you,” said Randy Hicks, M.D., MBA, radiologist, co-owner and CEO at Regional Medical Imaging. “It’s software you can trust to help diagnose cancers and improve workflow, keeping physicians on track and enabling them to read cases more quickly.”

Since the product was launched in the United States in December 2018, ProFound AI has been adopted by a significant number of high-profile hospitals and imaging centers in all major geographic areas of the country, demonstrating the strong need for such revolutionary technology.

“We are very pleased with the preliminary success and strong adoption of ProFound AI among some of the top luminary sites in the U.S.,” said Stacey Stevens, executive vice president and chief strategy and commercial officer at iCAD. “This strong initial adoption of ProFound AI now allows us to create powerful reference sites, customer testimonials and educational events that will further accelerate growth of this unprecedented solution. As the only FDA cleared provider of AI technology for digital breast tomosynthesis, we look forward to driving continued adoption, ultimately transforming breast cancer detection and improving patient lives.”

ProFound AI is a high-performance, deep-learning, cancer detection and workflow solution for DBT delivering critical benefits to radiologists, their facilities, and their patients through the improvement of cancer detection rates by an average of 8 percent and decreasing unnecessary patient recall rates by an average of 7 percent. The new technology has been trained to detect malignant soft-tissue densities and calcifications. It also provides radiologists with scoring information representing the likelihood that a detection or case is malignant based on the large dataset of clinical images used to train the algorithm.

“Following our recent implementation of ProFound AI from iCAD, we have already recognized the value and benefits it is providing to us in reading our DBT studies. Our radiologists appreciate this compelling technology and the high sensitivity and specificity it delivers in identifying lesion markings. It is imperative for us to continue providing the community with the best technology available to detect breast cancer, and our use of ProFound AI is indicative of this,” said Harold Tanenbaum, M.D., radiologist, medical director Marine Park Radiology, NY.

In addition to improving clinical performance related to breast cancer detection and false positive rates, study results showed that ProFound AI can reduce radiologists’ reading time by more than 50 percent on average. An increase in reading time has been a significant challenge for radiologists when moving from 2D to 3D mammography.

“We are proud to be using ProFound AI for DBT to assist our radiology team in providing improved quality patient care. Timing is critical for patients with hidden breast cancers, and the combination of 3D mammography and iCAD’s ProFound AI software could be life saving,” said John Ervin, imaging director for Hunt Regional Healthcare.

ProFound AI is currently available for use with leading DBT systems in the U.S., Canada and Europe. For more information about the solution and its benefits, visit www.icadmed.com.

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2018, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190314005904/en/

CONTACT: Media Inquiries:

ARPR, on behalf of iCAD, Inc.

Paul Barren, (855) 300-8209

paul@arpr.comInvestor Relations:

LifeSci Advisors

Jeremy Feffer, (212) 915-2568

jeremy@lifesciadvisors.com

KEYWORD: UNITED STATES NORTH AMERICA NEW HAMPSHIRE

INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE HEALTH MEDICAL DEVICES ONCOLOGY RADIOLOGY

SOURCE: iCAD, Inc.

Copyright Business Wire 2019.

PUB: 03/14/2019 05:29 PM/DISC: 03/14/2019 05:29 PM

http://www.businesswire.com/news/home/20190314005904/en

Related Posts:

  • No Related Posts